• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sensorion, Cochlear collab to study combo therapies for patients with cochlear implants

December 18, 2017 By Sarah Faulkner

Sensorion, CochlearSensorion, a biotech working on therapies for inner ear diseases, said today that it inked a deal with Cochlear Ltd (ASX:COH) to study combination therapies for patients with cochlear implants.

According to the deal, the companies will combine Sensorion’s SENS-401 compound with cochlear implants in preclinical studies starting next year. The drug-device therapies could be in clinical trials as early as 2019, the companies reported.

In connection with the deal, Cochlear is slated to invest $1.9 million in shares of Sensorion in exchange for the right of first negotiation for a global license to use SENS-401 in patients with certain implantable devices.

“Our collaboration has the potential to be transformational for both partners, as well as for patients suffering from hearing loss,” Sensorion CEO Nawal Ouzren said in prepared remarks. “In children, the sense of hearing is crucial to development, language and learning; in older adults, hearing impairment can be disabling and isolating. We believe that our collaborative efforts could ultimately result in life-changing benefits to implanted  patients and we look forward to initiating mid-stage clinical testing as soon as 2019.”

“Cochlear is committed to advance hearing therapies and we look forward to leveraging our combined knowledge and capabilities,” Jan Janssen, Cochlear’s CTO, added. “Sensorion has a promising portfolio of therapeutic candidates and we believe that the demonstrated effects of SENS-401 may strategically complement our technology. We are excited for what our combined efforts could mean for providing even better outcomes for implant recipients.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Preclinical Trials, Research & Development, Wall Street Beat Tagged With: cochlear, sensorion

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS